ADMA — ADMA BIOLOGICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1368514 ·
Last close
$8.15
Market Cap
$1.89B
52W High
$17.16
52W Low
$7.21
ADV30
6,722,864
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 114,493,000 | 80,750,000 | 50,294,000 | 45,328,000 | 665,184,000 | 138,153,000 | 274,859,000 |
| Dec 2025 | 139,163,000 | 88,816,000 | 62,751,000 | 49,379,000 | 624,242,000 | 87,630,000 | 146,922,000 |
| Sep 2025 | 134,224,000 | 75,626,000 | 51,012,000 | 36,428,000 | 568,687,000 | 61,385,000 | 137,501,000 |
| Jun 2025 | 121,984,000 | 67,227,000 | 42,798,000 | 34,219,000 | 558,380,000 | 90,285,000 | 160,055,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$50,396,000
Investing CF
$-21,891,000
Financing CF
$-44,022,000
CapEx
$-22,891,000
Dividends Paid
—
Buybacks
$-8,902,000
EPS Diluted TTM
$0.60
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-161,653,000
Inventory
$206,465,000
Receivables
$158,429,000
ST Investments
—
EBIT TTM
$189,767,000
Pretax Income TTM
$182,657,000
Interest Exp TTM
$7,110,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$509,864,000
EBITDA
$214,822,000
Free Cash Flow
$58,354,124
Enterprise Value
$43,657,355,264
Total Cash
$55,921,152,000
Total Debt
$97,668,702,208
Shares Out
231,772,715
Trailing EPS
$0.68
Book Value
$1.68
ROE
43.3%
ROA
22.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 510,173,000 | 191,443,000 | 146,930,000 | 624,242,000 | 146,922,000 | — | 50,396,000 |
| Dec 2024 | 426,454,000 | 138,983,000 | 197,673,000 | 488,678,000 | 139,660,000 | — | 118,672,000 |
| Dec 2023 | 258,215,000 | 21,632,000 | -28,239,000 | 329,182,000 | 193,976,000 | — | 8,800,000 |
| Dec 2022 | 154,080,000 | -39,365,000 | -65,904,000 | 348,461,000 | 196,487,000 | — | -59,508,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MESO | MESOBLAST LTD | $1.93B | $14.90 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $1.83B | $4.10 | — |
| VCEL | Vericel Corp | $1.79B | $34.97 | — |
| NVAX | NOVAVAX INC | $1.72B | $10.46 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.15B | $8.47 | — |
News headlines (Yahoo Finance, 1h cache)
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
2026-05-26 18:58 · Yahoo
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
2026-05-21 21:51 · Yahoo
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
2026-05-21 21:39 · Yahoo
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
2026-05-19 18:30 · Yahoo
How Channel Stuffing Probes and ASCENIV’s Pediatric Expansion Will Impact ADMA Biologics (ADMA) Investors
2026-05-15 20:21 · Yahoo
Here’s What Analysts Think About ADMA Biologics (ADMA)
2026-05-14 16:51 · Yahoo
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
2026-05-14 13:30 · Yahoo
New Strong Sell Stocks for May 14th
2026-05-14 09:32 · Yahoo
Canaccord Cuts PT on ADMA Biologics Inc. (ADMA) But Remains a Buy on Shares
2026-05-12 21:27 · Yahoo
New Strong Sell Stocks for May 11th
2026-05-11 09:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.